EUVIMEDEUVIMED entdecken
Crossref

Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome

Manuela Straub, Jürgen Kupferschläger, Lina Maria Serna Higuita, Matthias Weissinger, Helmut Dittmann, Christian la Fougère, Francesco Fiz

Journal of Nuclear Medicine · 2023-09 · 64 (9) · 1431-1438

DOI: 10.2967/jnumed.122.264770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.07.2023. Verfasst von Manuela Straub und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

177Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant prostate cancer (mCRPC). However, some patients progress under treatment. We hypothesized that the tracer kinetics within the metastases may influence the therapy effectiveness and tested this hypothesis by analyzing uptake parameters on 2 consecutive posttherapy SPECT/CT scans. Methods: mCRPC patients treated with 177Lu-PSMA-617 and with available posttherapy SPECT/CT imaging (24 and 48 h after the first treatment) were enrolled retrospectively. Volumes of interest were defined on lymph node metastasis (LNM) and bone metastasis (BM) on both SPECT/CT scans. The reduction of the percentage injected dose (%IDred) between the 2 SPECT/CT scans was computed. We compared %IDred of responders (prostate-specific antigen drop ≥ 50% after 2 cycles of 177Lu-PSMA-617) and nonresponders. We tested the association of %IDred with progression-free survival and overall survival (OS) using a univariate Kaplan-Meier (KM) analysis and a multivariate Cox regression model.

Results

Fifty-five patients (median age, 73 y; range, 54-87 y) were included. %IDred in LNM and BM was greater in nonresponders than in responders (for LNM, 36% in nonresponders [interquartile range (IQR), 26%-47%] vs. 24% in responders [IQR, 12%-33%] [P = 0.003]; for BM, 35% in nonresponders [IQR, 27%-52%] vs. 18% in responders [IQR, 15%-29%] [P = 0.002]). For progression-free survival, in KM analysis, greater %IDred in LNM (P = 0.008) and BM (P = 0.001) was associated with shorter survival, whereas in multivariate analysis, only %IDred in LNM was retained (P = 0.03). In univariate KM analysis of OS, greater %IDred in BM was associated with shorter survival (P = 0.002). In multivariate OS analysis, BM %IDred (P = 0.009) was retained.

Conclusion

The 177Lu-PSMA-617 clearance rate from mCRPC metastases appears to be a relevant prognosticator of response and survival, with faster clearing possibly signaling a shorter radiopharmaceutical residence time and absorbed dose. Dual-time-point analysis appears to be a feasible and readily available approach to estimate the likelihood of response and patients' survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansAgedRetrospective StudiesKineticsDipeptidesHeterocyclic Compounds, 1-RingSingle Photon Emission Computed Tomography Computed TomographyTreatment OutcomeLutetiumPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

177Lu-PSMA-617RLTSPECT/CTdual time pointmCRPC

Substanzen

PSMA-617Prostate-Specific AntigenDipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany.
  • Institute of Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.
  • Department of Radiology, University Hospital, Tübingen, Germany.
  • Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany; christian.lafougere@med.uni-tuebingen.de.
  • Cluster of Excellence 2180 "Image-Guided and Functionally Instructed Tumor Therapies," Eberhard Karls University, Tübingen, Germany.
  • German Cancer Consortium, German Cancer Research Center Partner Site Tübingen, Tübingen, Germany; and.

Zitieren

APA

Straub, M., Kupferschläger, J., Serna Higuita, L. M., Weissinger, M., Dittmann, H., la Fougère, C., & Fiz, F. (2023). Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome. Journal of Nuclear Medicine, 64(9), 1431-1438. https://doi.org/10.2967/jnumed.122.264770

Vancouver

Straub M, Kupferschläger J, Serna Higuita LM, Weissinger M, Dittmann H, la Fougère C, et al. Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome. Journal of Nuclear Medicine. 2023;64(9):1431-1438. doi:10.2967/jnumed.122.264770

BibTeX
@article{Straub2023,
  author = {Straub, Manuela and Kupferschläger, Jürgen and Serna Higuita, Lina Maria and Weissinger, Matthias and Dittmann, Helmut and la Fougère, Christian and Fiz, Francesco},
  title = {Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {9},
  pages = {1431--1438},
  doi = {10.2967/jnumed.122.264770}
}
Kostenlos starten →